Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2020 · 10-Q
Revenue$385.20M$385.20M+23.5% vs Q3 2019 Net Income$39.50M$39.50M−8.6% vs Q3 2019 EPS Diluted$0.73$0.73−12.0% vs Q3 2019 Operating Income$61,300,000−13.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$59,500,000N/M Margins · derivedOperating margin15.9%−6.8 pt vs Q3 2019
Net margin10.3%−3.6 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 6, 2020 · 37 d after period end